Gynecol Endocrinol 31(3):196201
Gina Vaynshteyn, Associate Vice President, Commerce at SheMedia, shares her experience below
Any treatment plan involving these agents should include: Regular blood tests (glucose, HbA1c, IGF-1, lipids, liver function, renal function) Documented informed consent regarding off-label or investigational use Dietitian input to monitor nutritional status, particularly during periods of rapid weight loss or reduced appetite Reconciliation of all concomitant medicines , including over-the-counter products and supplements, to minimise interaction risks Clear escalation pathways if side effects arise, including urgent review for severe abdominal pain, dehydration, or hypoglycaemia Ongoing review by a named responsible clinician Reporting of any suspected adverse effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) Your health and safety are best protected by working transparently within the NHS or a regulated private medical setting, with full disclosure of all medicines prescribed or otherwise that you are taking
The clinical principle is to titrate antihypertensives downward as weight loss progresses, not to discontinue abruptly
It activates certain pathways that lead to an increase in GLP-1 production
For example, you might discover that injecting at 7 PM produces less nausea than injecting at 9 PM because you are further from your last meal
%20(1).png)
